Rising Prevalence and Incidence of Kidney Diseases Fueling Idefirix Market Growth: A Key Factor Shaping the Future of the Idefirix Market in 2025

"What industry-specific factors are fueling the growth of the idefirix market?
The growth of the idefirix market is anticipated to be fueled by the escalating occurrence and prevalence of kidney diseases. These are ailments that impair the kidneys' ability to filter waste and maintain fluid equilibrium in the body by damaging their structure or function. The rising occurrence and prevalence of kidney diseases are often linked to factors such as aging populations, increased diabetes and hypertension rates, lifestyle decisions, and genetic predispositions. Idefirix, an innovative IgG-degrading enzyme treatment, aids those suffering from kidney diseases by allowing highly sensitized individuals to have critical kidney transplants by efficiently reducing the antibodies specific to the donor that could otherwise result in transplant rejection. For example, a UK-based kidney research group reported in June 2023 that the number of acute kidney injury cases is expected to rise from an estimated 615,000 in 2022 to 637,000 by 2033. Thus, the rising occurrence and prevalence of kidney diseases are key drivers propelling the growth of the idefirix market.

Get Your Idefirix Market Report Here:
https://www.thebusinessresearchcompany.com/report/idefirix-global-market-report

What Is the projected market size and growth rate for the idefirix market?
Recent years have seen the market size for idefirix expand by XX (HCAGR). Projections indicate growth from $XX million in 2024 to $XX million in 2025, tantamount to a compound annual growth rate (CAGR) of XX%. Factors contributing to this growth through the historic period include a surge in allergic diseases, amplified dosages of the medication, a growing occurrence of chronic illnesses, heightened requirement for organ transplants, and a rise in the prevalence and incidence of kidney-related diseases.

The market size for idefirix is projected to experience a compound annual growth rate (CAGR) of XX% and grow to $XX million in 2029. The anticipated growth over the forecast period can be attributed to factors such as an increase in the volume of kidney transplant waiting lists, heightened awareness about organ donation, expansion in research and development, a surge in procedure numbers and FDA approvals, as well as an increase in the understanding of antibody-mediated rejection. Significant trends in the forecast period include advances in the technology of antibody-cleaving enzymes, increased funding in transplant immunology research, strategic partnerships with transplant centers for clinical integration, a heightened emphasis on personalized medicine, and governmental efforts supporting organ transplantation.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20093&type=smp

What new trends are reshaping the idefirix market and its opportunities?
A predominant trend within the idefirix market is the focus on creating and developing inventive solutions like desensitization treatment for patients who are highly sensitive to kidney transplants. This medical approach aids in the removal or reduction of destructive antibodies, allowing patients to accept organs from donors they were previously incompatible with. For instance, in July 2023, an announcement was made by Hansa Biopharma, a biopharmaceutical establishment based in Sweden, revealing that Australia's regulatory authority, the Australian Therapeutic Goods Administration (TGA), had given its approval for Idefirix (imlifidase) to be used as a desensitization treatment for extremely sensitized kidney transplant patients. Thanks to this approval, the range of potential kidney donors for these patients increases to cover both living and deceased individuals. The treatment functions by reducing or eradicating harmful anti-donor antibodies that could otherwise block transplantation. This endorsement, based on the positive results from phase 2 studies conducted by Hansa Biopharma, highlighted an important development in increasing kidney transplant options for these vulnerable patients in Australia.

What major market segments define the scope and growth of the idefirix market?
The idefirix market covered in this report is segmented -

1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Application: Kidney Transplantation, Desensitization Protocols
3) By End-User: Hospitals, Specialized Clinics, Home Healthcare
4) By Distribution Channel: Direct Sales, Pharmacies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20093

Which region dominates the idefirix market?
Europe was the largest region in the idefirix market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the idefirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which key market leaders are driving the idefirix industry growth?
Major companies operating in the idefirix market include Hansa Biopharma AB

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20093&type=smp

What Is Covered In The Idefirix Global Market Report?

•Market Size Forecast: Examine the idefirix market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the idefirix market for a structured understanding.
•Key Players Overview: Analyze major players in the idefirix market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the idefirix market.
•Segment Contributions: Evaluate how different segments drive overall growth in the idefirix market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the idefirix market.
•Industry Challenges: Identify potential risks and obstacles affecting the idefirix market.
•Competitive Landscape: Review strategic developments in the idefirix market, including expansions, agreements, and new product launches.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.